Recent advances in osteosarcoma

Current Opinion in Pharmacology

Volumn 16, Issue 1, 2014, Pages 15-23

  Botter, Sander M ^a   Neri, Dario ^b   Fuchs, Bruno ^a  

^a BALGRIST UNIVERSITY HOSPITAL   (Switzerland)

^b ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MICRORNA; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BONE METABOLISM; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER RESEARCH; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CAUSE OF DEATH; DRUG TARGETING; ENZYME INHIBITION; HUMAN; IMMUNOMODULATION; IMMUNOSTIMULATION; METASTASIS; OSTEOSARCOMA; OSTEOSARCOMA CELL; PREVALENCE; PRIORITY JOURNAL; TREATMENT RESPONSE; VALIDATION STUDY; BONE; BONE NEOPLASMS; GENETICS; IMMUNOLOGY; METABOLISM; RESEARCH;

ANTINEOPLASTIC AGENTS; BONE AND BONES; BONE NEOPLASMS; HUMANS; MICRORNAS; OSTEOSARCOMA; RESEARCH;

EID: 84896305258     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2014.02.002     Document Type: Review

References (86)

1. J. Whelan, A. McTiernan, N. Cooper, Y.K. Wong, M. Francis, S. Vernon, and S.J. Strauss Incidence and survival of malignant bone sarcomas in England 1979-2007 Int J Cancer 131 2012 E508 E517
2. J. Gurney, A. Swensen, and M. Bulterys Malignant bone tumors L.A.G. Ries, M.A. Smith, J.G. Gurney, M. Linet, T. Tamra, J.L. Young, G.R. Bunin, Cancer Incidence and Survival Among Children and Adolescents: United States Seer Program 1975-1995, National Cancer Institute, Seer Program. NIH Pub. No. 99-4649, Bethesda, MD 1999
3. L.A.G. Ries Childhood cancer mortality L.A.G. Ries, M.A. Smith, J.G. Gurney, M. Linet, T. Tamra, J.L. Young, G.R. Bunin, Cancer Incidence and Survival Among Children and Adolescents: United States Seer Program 1975-1995, National Cancer Institute, Seer Program. NIH Pub. No. 99-4649, Bethesda, MD 1999
4. A.M. Linabery, and J.A. Ross Trends in childhood cancer incidence in the U.S (1992-2004) Cancer 112 2008 416 432
5. D.C. Allison, S.C. Carney, E.R. Ahlmann, A. Hendifar, S. Chawla, A. Fedenko, C. Angeles, and L.R. Menendez A meta-analysis of osteosarcoma outcomes in the modern medical era Sarcoma 2012 704872
6. B.J. Miller, P. Cram, C.F. Lynch, and J.A. Buckwalter Risk factors for metastatic disease at presentation with osteosarcoma: an analysis of the seer database J Bone Joint Surg Am 95 2013 e89
7. M.J. Klein, and G.P. Siegal Osteosarcoma: anatomic and histologic variants Am J Clin Pathol 125 2006 555 581
8. M.L. Kuijjer, P.C. Hogendoorn, and A.M. Cleton-Jansen Genome-wide analyses on high-grade osteosarcoma: making sense of a genomically most unstable tumor Int J Cancer 133 2013 2512 2521
9. P.J. Stephens, C.D. Greenman, B. Fu, F. Yang, G.R. Bignell, L.J. Mudie, E.D. Pleasance, K.W. Lau, D. Beare, and L.A. Stebbings et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development Cell 144 2011 27 40
10. B.S. Taylor, J. Barretina, R.G. Maki, C.R. Antonescu, S. Singer, and M. Ladanyi Advances in sarcoma genomics and new therapeutic targets Nat Rev Cancer 11 2011 541 557
11. M.R. Junttila, and F.J. de Sauvage Influence of tumour micro-environment heterogeneity on therapeutic response Nature 501 2013 346 354
12. A.B. Mohseny, K. Szuhai, S. Romeo, E.P. Buddingh, I. Briaire-de Bruijn, D. de Jong, M. van Pel, A.M. Cleton-Jansen, and P.C. Hogendoorn Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of cdkn2 J Pathol 219 2009 294 305
13. A.J. Ng, A.J. Mutsaers, E.K. Baker, and C.R. Walkley Genetically engineered mouse models and human osteosarcoma Clin Sarcoma Res 2 2012 19
14. F.S. Dela Cruz Cancer stem cells in pediatric sarcomas Front Oncol 3 2013 168
15. V. Tirino, V. Desiderio, F. Paino, G. Papaccio, and M. De Rosa Methods for cancer stem cell detection and isolation Methods Mol Biol 879 2012 513 529
16. C. Blanpain, and B.D. Simons Unravelling stem cell dynamics by lineage tracing Nat Rev Mol Cell Biol 14 2013 489 502
17. S. Yamanaka, and H.M. Blau Nuclear reprogramming to a pluripotent state by three approaches Nature 465 2010 704 712
18. C.L. Chaffer, I. Brueckmann, C. Scheel, A.J. Kaestli, P.A. Wiggins, L.O. Rodrigues, M. Brooks, F. Reinhardt, Y. Su, and K. Polyak et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state Proc Natl Acad Sci U S A 108 2011 7950 7955
19. M. Trucco, and D. Loeb Sarcoma stem cells: do we know what we are looking for? Sarcoma 2012 2012 291705
20. A.M. van Maldegem, A. Bhosale, H.J. Gelderblom, P.C. Hogendoorn, and A.B. Hassan Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and ewing sarcoma confirms limited outcomes and need for translational investment Clin Sarcoma Res 2 2012 5
21. A. Luetke, P.A. Meyers, I. Lewis, and H. Juergens Osteosarcoma treatment - where do we stand? A state of the art review Cancer Treat Rev 2013 10.1016/j.ctrv.2013.11.006
22. S. Ferrari, P. Ruggieri, G. Cefalo, A. Tamburini, R. Capanna, F. Fagioli, A. Comandone, R. Bertulli, G. Bisogno, and E. Palmerini et al. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an italian sarcoma group trial ISG/OS-1 J Clin Oncol 30 2012 2112 2118
23. F. Duffaud, G. Egerer, S. Ferrari, H. Rassam, U. Boecker, and B. Bui-Nguyen A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma Eur J Cancer 48 2012 564 570
24. A.B. Warwick, S. Malempati, M. Krailo, A. Melemed, R. Gorlick, M.M. Ames, S.L. Safgren, P.C. Adamson, and S.M. Blaney Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: a children's oncology group study Pediatr Blood Cancer 60 2013 237 241
25. E. Fox, S. Patel, J.K. Wathen, S. Schuetze, S. Chawla, D. Harmon, D. Reinke, R. Chugh, R.S. Benjamin, and L.J. Helman Phase II study of sequential gemcitabine followed by docetaxel for recurrent ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of sarcoma alliance for research through collaboration study 003 Oncologist 17 2012 321
26. ®, ET-743) in children and adolescents with relapsed or refractory solid tumors Pediatr Blood Cancer 59 2012 865 869
27. S. Baruchel, A. Pappo, M. Krailo, K.S. Baker, B. Wu, D. Villaluna, M. Lee-Scott, P.C. Adamson, and S.M. Blaney A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the children's oncology group Eur J Cancer 48 2012 579 585
28. L. Gastaud, E. Saada-Bouzid, V. Le Morvan, P. Pourquier, A. Ianessi, J. Thariat, A. Italiano, and A. Thyss Major efficacy of trabectedin in 2 metastatic osteosarcoma patients with wild-type Asp1104 ERCC5 tumor status Onkologie 36 2013 670 673
29. M. D'Incalci, and C.M. Galmarini A review of trabectedin (ET-743): a unique mechanism of action Mol Cancer Ther 9 2010 2157 2163
30. H. Strander Interferons and osteosarcoma Cytokine Growth Factor Rev 18 2007 373 380 (Pubitemid 47302835)
31. K.A. Parato, C.J. Breitbach, F. Le Boeuf, J. Wang, C. Storbeck, C. Ilkow, J.S. Diallo, T. Falls, J. Burns, and V. Garcia et al. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers Mol Ther 20 2012 749 758
32. C.A. Arndt, N.V. Koshkina, C.Y. Inwards, D.S. Hawkins, M.D. Krailo, D. Villaluna, P.M. Anderson, A.M. Goorin, M.L. Blakely, and M. Bernstein et al. Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. A report from the children's oncology group Clin Cancer Res 16 2010 4024 4030
33. A. Spreafico, S. Schenone, T. Serchi, M. Orlandini, A. Angelucci, D. Magrini, G. Bernardini, G. Collodel, A. Di Stefano, and C. Tintori et al. Antiproliferative and proapoptotic activities of new pyrazolo[3,4-d]pyrimidine derivative src kinase inhibitors in human osteosarcoma cells FASEB J 22 2008 1560 1571 (Pubitemid 351656796)
34. P. Hingorani, W. Zhang, R. Gorlick, and E.A. Kolb Inhibition of src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo Clin Cancer Res 15 2009 3416 3422
35. T.A. Yap, H.T. Arkenau, D.R. Camidge, S. George, N.J. Serkova, S.J. Gwyther, J.L. Spratlin, R. Lal, J. Spicer, and N.M. Desouza et al. First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies Clin Cancer Res 19 2013 909 919
36. H.K. Brown, and I. Holen Anti-tumour effects of bisphosphonates - what have we learned from in vivo models? Curr Cancer Drug Targets 9 2009 807 823
37. B. Kubista, K. Trieb, F. Sevelda, C. Toma, F. Arrich, P. Heffeter, L. Elbling, H. Sutterluty, K. Scotlandi, and R. Kotz et al. Anticancer effects of zoledronic acid against human osteosarcoma cells J Orthop Res 24 2006 1145 1152 (Pubitemid 43870876)
38. P.A. Meyers, J.H. Healey, A.J. Chou, L.H. Wexler, P.R. Merola, C.D. Morris, M.P. Laquaglia, M.G. Kellick, S.J. Abramson, and R. Gorlick Addition of pamidronate to chemotherapy for the treatment of osteosarcoma Cancer 117 2011 1736 1744
39. R.E. Goldsby, T.M. Fan, D. Villaluna, L.M. Wagner, M.S. Isakoff, J. Meyer, R.L. Randall, S. Lee, G. Kim, and M. Bernstein et al. Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the children's oncology group Eur J Cancer 49 2013 2384 2391
40. P.A. Meyers, C.L. Schwartz, M.D. Krailo, J.H. Healey, M.L. Bernstein, D. Betcher, W.S. Ferguson, M.C. Gebhardt, A.M. Goorin, and M. Harris et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival - a report from the children's oncology group J Clin Oncol 26 2008 633 638 (Pubitemid 351264359)
41. M.A. Richardson, T. Ramirez, N.C. Russell, and L.A. Moye Coley toxins immunotherapy: a retrospective review Altern Ther Health Med 5 1999 42 47
42. L.M. Jeys, R.J. Grimer, S.R. Carter, R.M. Tillman, and A. Abudu Post operative infection and increased survival in osteosarcoma patients: are they associated? Ann Surg Oncol 14 2007 2887 2895 (Pubitemid 47460646)
43. B.D. Lascelles, W.S. Dernell, M.T. Correa, M. Lafferty, C.M. Devitt, C.A. Kuntz, R.C. Straw, and S.J. Withrow Improved survival associated with postoperative wound infection in dogs treated with limb-salvage surgery for osteosarcoma Ann Surg Oncol 12 2005 1073 1083 (Pubitemid 41660684)
44. J.F. Modiano, D. Bellgrau, G.R. Cutter, S.E. Lana, N.P. Ehrhart, E. Ehrhart, V.L. Wilke, J.B. Charles, S. Munson, and M.C. Scott et al. Inflammation, apoptosis, and necrosis induced by neoadjuvant fas ligand gene therapy improves survival of dogs with spontaneous bone cancer Mol Ther 20 2012 2234 2243
45. J.M. Goldberg Immunotherapy of sarcomas Curr Opin Oncol 25 2013 390 397
46. B. Wiemann, and C.O. Starnes Coley's toxins, tumor necrosis factor and cancer research: a historical perspective Pharmacol Ther 64 1994 529 564 (Pubitemid 24381235)
47. E.S. Kleinerman, S.F. Jia, J. Griffin, N.L. Seibel, R.S. Benjamin, and N. Jaffe Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration J Clin Oncol 10 1992 1310 1316
48. K. Venkatakrishnan, W.G. Kramer, T.W. Synold, D.B. Goodman, E. Sides 3rd, and C. Oliva A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteers Eur J Clin Pharmacol 68 2012 1347 1355
49. J.P. Deroose, A.M. Eggermont, A.N. van Geel, J.W. Burger, M.A. den Bakker, J.H. de Wilt, and C. Verhoef Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas J Clin Oncol 29 2011 4036 4044
50. D.J. Grunhagen, J.H. de Wilt, T.L. ten Hagen, and A.M. Eggermont Technology insight: utility of tnf-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities Nat Clin Pract Oncol 3 2006 94 103 (Pubitemid 43250430)
51. A. Bhangu, L. Broom, D. Nepogodiev, D. Gourevitch, and A. Desai Outcomes of isolated limb perfusion in the treatment of extremity soft tissue sarcoma: a systematic review Eur J Surg Oncol 39 2013 311 319
52. T. Hemmerle, P. Probst, L. Giovannoni, A.J. Green, T. Meyer, and D. Neri The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity Br J Cancer 109 2013 1206 1213
53. G. Spitaleri, R. Berardi, C. Pierantoni, T. De Pas, C. Noberasco, C. Libbra, R. Gonzalez-Iglesias, L. Giovannoni, A. Tasciotti, and D. Neri et al. Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein l19-TNF in patients with advanced solid tumours J Cancer Res Clin Oncol 139 2013 447 455
54. F. Papadia, V. Basso, R. Patuzzo, A. Maurichi, A. Di Florio, L. Zardi, E. Ventura, R. Gonzalez-Iglesias, V. Lovato, and L. Giovannoni et al. Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein l19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma J Surg Oncol 107 2013 173 179
55. S. Hoving, S.T. van Tiel, A.M. Eggermont, and T.L. ten Hagen Effect of low-dose tumor necrosis factor-alpha in combination with stealth liposomal cisplatin (SPI-077) on soft-tissue- and osteosarcoma-bearing rats Anticancer Res 25 2005 743 750 (Pubitemid 40546840)
56. A.H. van der Veen, J.H. de Wilt, A.M. Eggermont, S.T. van Tiel, A.L. Seynhaeve, and T.L. ten Hagen TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects Br J Cancer 82 2000 973 980 (Pubitemid 30085254)
57. F. Lamoureux, P. Richard, Y. Wittrant, S. Battaglia, P. Pilet, V. Trichet, F. Blanchard, F. Gouin, B. Pitard, and D. Heymann et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption Cancer Res 67 2007 7308 7318 (Pubitemid 47206560)
58. L. Endo-Munoz, A. Evdokiou, and N.A. Saunders The role of osteoclasts and tumour-associated macrophages in osteosarcoma metastasis Biochim Biophys Acta 1826 2012 434 442
59. S.A. Savage, L. Mirabello, Z. Wang, J.M. Gastier-Foster, R. Gorlick, C. Khanna, A.M. Flanagan, R. Tirabosco, I.L. Andrulis, and J.S. Wunder et al. Genome-wide association study identifies two susceptibility loci for osteosarcoma Nat Genet 45 2013 799 803
60. J. Rousseau, V. Escriou, F. Lamoureux, R. Brion, J. Chesneau, S. Battaglia, J. Amiaud, D. Scherman, D. Heymann, and F. Redini et al. Formulated sirnas targeting rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models J Bone Miner Res 26 2011 2452 2462
61. K. Ando, K. Mori, F. Redini, and D. Heymann RANKL/RANK/OPG: key therapeutic target in bone oncology Curr Drug Discov Technol 5 2008 263 268
62. G. Zhou, X. Shi, J. Zhang, S. Wu, and J. Zhao Micrornas in osteosarcoma: from biological players to clinical contributors: a review J Int Med Res 41 2013 1 12
63. Y. Gao, L.H. Luo, S. Li, and C. Yang miR-17 inhibitor suppressed osteosarcoma tumor growth and metastasis via increasing pten expression Biochem Biophys Res Commun 444 2014 230 234
64. L. Shen, X.D. Chen, and Y.H. Zhang MicroRNA-128 promotes proliferation in osteosarcoma cells by downregulating PTEN Tumour Biol 2013 10.1007/s13277-013- 1274-1
65. G. Zhao, C. Cai, T. Yang, X. Qiu, B. Liao, W. Li, Z. Ji, J. Zhao, H. Zhao, and M. Guo et al. MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma PLoS ONE 8 2013 e53906
66. H. Zhao, M. Guo, G. Zhao, Q. Ma, B. Ma, X. Qiu, and Q. Fan miR-183 inhibits the metastasis of osteosarcoma via downregulation of the expression of Ezrin in F5M2 cells Int J Mol Med 30 2012 1013 1020
67. J. Zhu, Y. Feng, Z. Ke, Z. Yang, J. Zhou, X. Huang, and L. Wang Down-regulation of Mir-183 promotes migration and invasion of osteosarcoma by targeting Ezrin Am J Pathol 180 2012 2440 2451
68. A.A. Sabile, M.J. Arlt, R. Muff, B. Bode, B. Langsam, J. Bertz, T. Jentzsch, G.J. Puskas, W. Born, and B. Fuchs Cyr61 expression in osteosarcoma indicates poor prognosis and promotes intratibial growth and lung metastasis in mice J Bone Miner Res 27 2012 58 67
69. J. Huang, K. Gao, J. Lin, and Q. Wang MicroRNA-100 inhibits osteosarcoma cell proliferation by targeting Cyr61 Tumour Biol 35 2013 1095 1100
70. W. Liang, B. Gao, P. Fu, S. Xu, Y. Qian, and Q. Fu The miRNAs in the pathgenesis of osteosarcoma Front Biosci (Landmark Ed) 18 2013 788 794
71. M. Nugent Microrna function and dysregulation in bone tumors: the evidence to date Cancer Manag Res 6 2014 15 25
72. R. Garzon, G. Marcucci, and C.M. Croce Targeting micrornas in cancer: rationale, strategies and challenges Nat Rev Drug Discov 9 2010 775 789
73. Y. Zhang, H. Hu, L. Song, L. Cai, R. Wei, and W. Jin Epirubicin-mediated expression of miR-302b is involved in osteosarcoma apoptosis and cell cycle regulation Toxicol Lett 222 2013 1 9
74. J. Yang, and W. Zhang New molecular insights into osteosarcoma targeted therapy Curr Opin Oncol 25 2013 398 406
75. P.J. Houghton, C.L. Morton, C. Tucker, D. Payne, E. Favours, C. Cole, R. Gorlick, E.A. Kolb, W. Zhang, and R. Lock et al. The pediatric preclinical testing program: description of models and early testing results Pediatr Blood Cancer 49 2007 928 940 (Pubitemid 350022448)
76. V.B. Sampson, R. Gorlick, D. Kamara, and E. Anders Kolb A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma Front Oncol 3 2013 132
77. H.H. Luu, Q. Kang, J.K. Park, W. Si, Q. Luo, W. Jiang, H. Yin, A.G. Montag, M.A. Simon, and T.D. Peabody et al. An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis Clin Exp Metastasis 22 2005 319 329 (Pubitemid 41374288)
78. A.J. Mutsaers, A.J. Ng, E.K. Baker, M.R. Russell, A.M. Chalk, M. Wall, B.J. Liddicoat, P.W. Ho, J.L. Slavin, and A. Goradia et al. Modeling distinct osteosarcoma subtypes in vivo using Cre: lox and lineage-restricted transgenic shRNA Bone 55 2013 166 178
79. J.L. Rowell, D.O. McCarthy, and C.E. Alvarez Dog models of naturally occurring cancer Trends Mol Med 17 2011 380 388
80. F. Mueller, B. Fuchs, and B. Kaser-Hotz Comparative biology of human and canine osteosarcoma Anticancer Res 27 2007 155 164 (Pubitemid 46370589)
81. M. Paoloni, S. Davis, S. Lana, S. Withrow, L. Sangiorgi, P. Picci, S. Hewitt, T. Triche, P. Meltzer, and C. Khanna Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression BMC Genomics 10 2009 625
82. M.C. Scott, A.L. Sarver, K.J. Gavin, V. Thayanithy, D.M. Getzy, R.A. Newman, G.R. Cutter, K. Lindblad-Toh, W.C. Kisseberth, and L.E. Hunter et al. Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach Bone 49 2011 356 367
83. K.S. Rankin, M. Starkey, J. Lunec, C.H. Gerrand, S. Murphy, and S. Biswas Of dogs and men: comparative biology as a tool for the discovery of novel biomarkers and drug development targets in osteosarcoma Pediatr Blood Cancer 58 2012 327 333
84. N.R. Monks, D.M. Cherba, S.G. Kamerling, H. Simpson, A.W. Rusk, D. Carter, E. Eugster, M. Mooney, R. Sigler, and M. Steensma et al. A multi-site feasibility study for personalized medicine in canines with osteosarcoma J Transl Med 11 2013 158
85. T. Hemmerle, and D. Neri The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer Int J Cancer 134 2013 467 477
86. G.L. Poli, C. Banchi, G. Virotta, A. Bettini, R. Moretti, E. Trachsel, G. Elia, L. Giovannoni, D. Neri, and A. Bruno Radretumab radioimmunotherapy in patients with brain metastasis: a 124I-L19SIP dosimetric pet study Cancer Immunol Res 2013 1